Public Sector Pension Investment Board Raises Position in TransMedics Group, Inc. $TMDX

Public Sector Pension Investment Board increased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 15.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 132,972 shares of the company’s stock after purchasing an additional 17,637 shares during the period. Public Sector Pension Investment Board owned 0.39% of TransMedics Group worth $14,919,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Whittier Trust Co. of Nevada Inc. grew its holdings in TransMedics Group by 981.0% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after buying an additional 206 shares during the period. Salomon & Ludwin LLC acquired a new stake in shares of TransMedics Group in the third quarter worth approximately $28,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of TransMedics Group in the second quarter worth approximately $48,000. Pilgrim Partners Asia Pte Ltd purchased a new stake in TransMedics Group in the third quarter valued at approximately $40,000. Finally, First Horizon Corp acquired a new position in TransMedics Group during the third quarter worth approximately $43,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other TransMedics Group news, Director David Weill sold 5,000 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total value of $693,200.00. Following the completion of the sale, the director owned 12,134 shares of the company’s stock, valued at $1,682,257.76. This trade represents a 29.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Gerardo Hernandez sold 920 shares of the business’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total transaction of $128,450.40. Following the transaction, the chief financial officer directly owned 15,064 shares in the company, valued at approximately $2,103,235.68. The trade was a 5.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 8,920 shares of company stock worth $1,257,310 in the last 90 days. 7.00% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Canaccord Genuity Group lifted their price target on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Needham & Company LLC increased their target price on TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Piper Sandler reissued an “overweight” rating on shares of TransMedics Group in a research report on Monday, December 22nd. Wall Street Zen upgraded TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Morgan Stanley lifted their price objective on TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, TransMedics Group presently has a consensus rating of “Moderate Buy” and an average price target of $144.25.

TransMedics Group Trading Up 1.0%

NASDAQ:TMDX opened at $129.84 on Friday. The business’s 50-day moving average is $132.32 and its two-hundred day moving average is $125.42. The firm has a market capitalization of $4.44 billion, a PE ratio of 52.57 and a beta of 2.06. TransMedics Group, Inc. has a 12 month low of $62.07 and a 12 month high of $156.00. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.